Patient experiences with clinical confirmatory genetic testing after using direct-to-consumer raw DNA and third-party genetic interpretation services

被引:2
|
作者
Dolphyn, Tiffany T. Nguyen [1 ,2 ]
Ormond, Kelly E. [1 ,3 ,4 ]
Weissman, Scott M. [5 ]
Kim, Helen J. [1 ]
Reuter, Chloe M. [6 ]
机构
[1] Stanford Univ, Stanford Sch Med, Dept Genet, Stanford, CA 94305 USA
[2] Stanford Univ, Stanford Sch Med, Stanford Med Clin Genom Program, Stanford, CA 94305 USA
[3] Stanford Univ, Stanford Ctr Biomed Eth, Stanford Sch Med, Stanford, CA 94305 USA
[4] Swiss Fed Inst Technol, Hlth Eth & Policy Lab, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland
[5] Chicago Genet Consultants, Northbrook, IL 60062 USA
[6] Stanford Hlth Care, Stanford Ctr Inherited Cardiovasc Dis, Stanford, CA 94305 USA
关键词
Raw DNA; Third-party interpretation; Direct-to-consumer; Genetic testing; Precision medicine; Personal utility; FALSE-POSITIVE MAMMOGRAMS; PRIMARY-CARE PHYSICIANS; PERSONAL UTILITY; QUALITATIVE RESEARCH; CONSEQUENCES; IMPACT;
D O I
10.1093/tbm/ibac083
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lay Summary The availability of raw DNA data and online genetic interpretation tools allow individuals to access genetic health risk information, where false-positive results exist. Little is known about the experience of individuals who discover disease-causing variant(s) through raw DNA interpretation and follow-up with medical-grade confirmatory genetic testing. This qualitative study describes the experiences of individuals who pursued medical-grade confirmatory genetic testing in the U.S. after they discovered a potential disease-causing variant in a raw DNA interpretation report. Individuals participated in semi-structured interviews, which were transcribed and inductively coded to identify themes. Of the 12 participants, 3 received medical-grade genetic testing results that confirmed disease-causing variants noted in raw DNA interpretation reports, and 9 were not confirmed. Nearly all participants described emotional distress and information-seeking behavior after discovering a disease-causing variant in raw DNA interpretation. When pursuing confirmatory genetic testing, many faced challenges with finding knowledgeable healthcare providers and obtaining insurance coverage. Despite reporting concerns over raw DNA interpretation and a desire for more safeguards, almost all participants stated interest in using the service again. Overall, participants' experiences reveal they find personal utility in raw DNA interpretation results and provide insight into opportunities for patient and provider education. This qualitative study describes the experiences of individuals who pursued clinical confirmatory genetic testing after obtaining raw DNA data from direct-to-consumer genetic testing and discovering a potential disease-causing variant from an online genetic interpretation tool. The availability of raw DNA and genetic interpretation tools allow individuals to access genetic health risk information, where analytical false-positives exist. Little is known about the experience of individuals who receive pathogenic or likely pathogenic variant(s) through raw DNA interpretation and follow-up with clinical confirmatory genetic testing. This qualitative study set out to describe the experiences of individuals who pursued clinical confirmatory genetic testing, including their perception of the process. Participants were recruited from social media and eligible if they discovered a potential pathogenic or likely pathogenic variant in a raw DNA interpretation report, completed clinical confirmatory genetic testing in the U.S., and provided documentation of those results. Individuals participated in semi-structured interviews, which were transcribed and inductively coded to identify themes. Of the 12 participants, 3 received clinical genetic testing results that confirmed pathogenic or likely pathogenic variants noted in raw DNA interpretation reports (confirmation positive), and 9 were not confirmed. Nearly all (n = 11) participants described emotional distress and information-seeking behavior as a coping mechanism after discovering a pathogenic or likely pathogenic variant in raw DNA interpretation. When pursuing confirmatory genetic testing, many (n = 9) faced challenges with finding knowledgeable healthcare providers and obtaining insurance coverage. Despite reporting concerns over raw DNA interpretation and a desire for more safeguards, almost all (n = 10) participants stated interest in using the service again. Overall, participants' experiences reveal they find personal utility in raw DNA interpretation results and provide insight into opportunities for patient and provider education.
引用
收藏
页码:104 / 114
页数:11
相关论文
共 30 条
  • [21] "It's our DNA, we deserve the right to test!" A content analysis of a petition for the right to access direct-to-consumer genetic testing
    Su, Yeyang
    Borry, Pascal
    Otte, Ina C.
    Howard, Heidi C.
    PERSONALIZED MEDICINE, 2013, 10 (07) : 729 - 739
  • [22] Considerations for developing regulations for direct-to-consumer genetic testing: a scoping review using the 3-I framework
    Cernat, Alexandra
    Bashir, Naazish S.
    Ungar, Wendy J.
    JOURNAL OF COMMUNITY GENETICS, 2022, 13 (02) : 155 - 170
  • [23] The effect of disease risk probability and disease type on interest in clinic-based versus direct-to-consumer genetic testing services
    Kerry Sherman
    Laura-Kate Shaw
    Katrina Champion
    Fernanda Caldeira
    Margaret McCaskill
    Journal of Behavioral Medicine, 2015, 38 : 706 - 714
  • [24] Genetic Testing Integration Panels (GTIPs): A Novel Approach for Considering Integration of Direct-To-Consumer and Other New Genetic Tests into Patient Care
    Uhlmann, Wendy R.
    Sharp, Richard R.
    JOURNAL OF GENETIC COUNSELING, 2012, 21 (03) : 374 - 381
  • [25] Are providers prepared for genomic medicine: interpretation of Direct-to-Consumer genetic testing (DTC-GT) results and genetic self-efficacy by medical professionals
    McGrath, Scott P.
    Walton, Nephi
    Williams, Marc S.
    Kim, Katherine K.
    Bastola, Kiran
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [26] Are providers prepared for genomic medicine: interpretation of Direct-to-Consumer genetic testing (DTC-GT) results and genetic self-efficacy by medical professionals
    Scott P. McGrath
    Nephi Walton
    Marc S. Williams
    Katherine K. Kim
    Kiran Bastola
    BMC Health Services Research, 19
  • [27] Considerations for developing regulations for direct-to-consumer genetic testing: a scoping review using the 3-I framework
    Alexandra Cernat
    Naazish S. Bashir
    Wendy J. Ungar
    Journal of Community Genetics, 2022, 13 : 155 - 170
  • [28] Veterinary care providers recognize clinical utility of genetic testing but report limited confidence in interpreting direct-to-consumer results
    Bennett, Nikki E.
    Johnson, Elizabeth A.
    Gray, Peter B.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2025, 86 (02)
  • [29] Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: A naturally-occuring experiment
    Mouchawar, J
    Hensley-Alford, S
    Laurion, S
    Ellis, J
    Kulchak-Rahm, A
    Finucane, ML
    Meenan, R
    Axell, L
    Pollack, R
    Ritzwoller, D
    GENETICS IN MEDICINE, 2005, 7 (03) : 191 - 197
  • [30] Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores
    Folkersen, Lasse
    Pain, Oliver
    Ingason, Andres
    Werge, Thomas
    Lewis, Cathryn M.
    Austin, Jehannine
    FRONTIERS IN GENETICS, 2020, 11